JPWO2019190879A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019190879A5 JPWO2019190879A5 JP2021502704A JP2021502704A JPWO2019190879A5 JP WO2019190879 A5 JPWO2019190879 A5 JP WO2019190879A5 JP 2021502704 A JP2021502704 A JP 2021502704A JP 2021502704 A JP2021502704 A JP 2021502704A JP WO2019190879 A5 JPWO2019190879 A5 JP WO2019190879A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- glial
- marker
- disease
- glial cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024063938A JP7697096B2 (ja) | 2018-03-27 | 2024-04-11 | 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療 |
| JP2025097962A JP2025123315A (ja) | 2018-03-27 | 2025-06-11 | 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862648684P | 2018-03-27 | 2018-03-27 | |
| US62/648,684 | 2018-03-27 | ||
| PCT/US2019/023395 WO2019190879A1 (en) | 2018-03-27 | 2019-03-21 | Car-treg-based therapies for treating neurodegenerative diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024063938A Division JP7697096B2 (ja) | 2018-03-27 | 2024-04-11 | 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021531280A JP2021531280A (ja) | 2021-11-18 |
| JPWO2019190879A5 true JPWO2019190879A5 (enExample) | 2022-03-24 |
Family
ID=68060734
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502704A Pending JP2021531280A (ja) | 2018-03-27 | 2019-03-21 | 神経変性疾患を処置するためのＣＡＲ−Ｔｒｅｇベースの治療 |
| JP2024063938A Active JP7697096B2 (ja) | 2018-03-27 | 2024-04-11 | 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療 |
| JP2025097962A Pending JP2025123315A (ja) | 2018-03-27 | 2025-06-11 | 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024063938A Active JP7697096B2 (ja) | 2018-03-27 | 2024-04-11 | 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療 |
| JP2025097962A Pending JP2025123315A (ja) | 2018-03-27 | 2025-06-11 | 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12173030B2 (enExample) |
| EP (1) | EP3773629A4 (enExample) |
| JP (3) | JP2021531280A (enExample) |
| KR (2) | KR102892999B1 (enExample) |
| CN (1) | CN112867496A (enExample) |
| AU (1) | AU2019242381B2 (enExample) |
| CA (1) | CA3095298A1 (enExample) |
| WO (1) | WO2019190879A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102892999B1 (ko) | 2018-03-27 | 2025-11-28 | 아즈테라피즈 인코포레이티드 | 신경변성 질환을 치료하기 위한 CAR-Treg-기반 요법 |
| CN116134144A (zh) | 2020-04-23 | 2023-05-16 | Az治疗股份有限公司 | 细胞的hla-i类mhc消融 |
| US20230210899A1 (en) * | 2020-05-28 | 2023-07-06 | Aztherapies, Inc. | CAR-Treg-Based Therapies Targeting Myelin Oligodendrocyte Glycoprotein (MOG) for Treating Neurodegenerative Diseases |
| CN117957246A (zh) * | 2021-09-03 | 2024-04-30 | 桑格摩生物治疗股份有限公司 | Mog结合蛋白和其用途 |
| WO2023047098A2 (en) * | 2021-09-21 | 2023-03-30 | Quell Therapeutics Ltd | Anti-p75ntr chimeric antigen receptor |
| GB202113674D0 (en) | 2021-09-24 | 2021-11-10 | Reflection Therapeutics Ltd | Targeted cell therapies |
| GB202113673D0 (en) | 2021-09-24 | 2021-11-10 | Reflection Therapeutics Ltd | Targeted cell therapies |
| CN118272314A (zh) * | 2024-04-15 | 2024-07-02 | 华中科技大学同济医学院附属同济医院 | 一种具有良好血脑屏障通透性的car-t细胞、产品及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007140971A2 (en) * | 2006-06-06 | 2007-12-13 | F. Hoffmann-La Roche Ag | Cell adhesion proteins as biomarker for alzheimer's disease |
| EP2046828A2 (en) | 2006-07-07 | 2009-04-15 | Wyeth | Nogo receptor functional motifs, peptide mimetics, and mutated functional motifs related thereto, and methods of using the same |
| US8790642B2 (en) * | 2008-08-29 | 2014-07-29 | Genentech, Inc. | Cross-reactive and bispecific anti-IL-17A/F antibodies |
| SG10201602159VA (en) * | 2011-02-11 | 2016-04-28 | Sloan Kettering Inst Cancer | Hla-restricted, peptide-specific antigen binding proteins |
| KR20140071277A (ko) * | 2011-05-19 | 2014-06-11 | 타이제닉스, 에스.에이.유. | 면역조절 활성을 갖는 세포 집단, 그의 제조 방법 및 용도 |
| CN103965357B (zh) * | 2013-12-31 | 2016-08-17 | 嘉和生物药业有限公司 | 一种抗人rankl抗体 |
| ES3051035T3 (en) | 2014-12-30 | 2025-12-23 | The Brigham And Womens Hospital Inc | Methods to improve cell therapy |
| WO2016161372A1 (en) * | 2015-04-01 | 2016-10-06 | President And Fellows Of Harvard College | Immunoconjugates for programming or reprogramming of cells |
| MX393951B (es) * | 2015-04-07 | 2025-03-24 | Alector Llc | Anticuerpos antisortilina y métodos para su uso. |
| CN109072194B (zh) | 2015-12-09 | 2022-12-27 | 纪念斯隆-凯特林癌症中心 | 免疫细胞组合物及其使用方法 |
| CN111357090B (zh) * | 2017-11-11 | 2024-01-05 | 微材料有限责任公司 | 用于高压处理腔室的气体输送系统 |
| KR102892999B1 (ko) | 2018-03-27 | 2025-11-28 | 아즈테라피즈 인코포레이티드 | 신경변성 질환을 치료하기 위한 CAR-Treg-기반 요법 |
| US20230210899A1 (en) | 2020-05-28 | 2023-07-06 | Aztherapies, Inc. | CAR-Treg-Based Therapies Targeting Myelin Oligodendrocyte Glycoprotein (MOG) for Treating Neurodegenerative Diseases |
-
2019
- 2019-03-21 KR KR1020207030758A patent/KR102892999B1/ko active Active
- 2019-03-21 JP JP2021502704A patent/JP2021531280A/ja active Pending
- 2019-03-21 US US17/041,835 patent/US12173030B2/en active Active
- 2019-03-21 CA CA3095298A patent/CA3095298A1/en active Pending
- 2019-03-21 AU AU2019242381A patent/AU2019242381B2/en active Active
- 2019-03-21 CN CN201980035934.XA patent/CN112867496A/zh active Pending
- 2019-03-21 EP EP19776538.1A patent/EP3773629A4/en active Pending
- 2019-03-21 WO PCT/US2019/023395 patent/WO2019190879A1/en not_active Ceased
- 2019-03-21 KR KR1020257039577A patent/KR20250174989A/ko active Pending
-
2024
- 2024-04-11 JP JP2024063938A patent/JP7697096B2/ja active Active
- 2024-11-01 US US18/934,745 patent/US20250129158A1/en active Pending
-
2025
- 2025-06-11 JP JP2025097962A patent/JP2025123315A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Huebner et al. | Axon regeneration in the peripheral and central nervous systems | |
| NZ591130A (en) | Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof | |
| JPWO2019190879A5 (enExample) | ||
| JP2024540221A (ja) | Ａａｖカプシドバリアント及びその使用 | |
| HRP20180516T1 (hr) | Humanizirana protutijela specifična za protofibrilni oblik amiloidnog-beta peptida | |
| NO20083793L (no) | Antistoffer mot amyloid-beta peptid | |
| RU2013120318A (ru) | Антитела, связывающие il-4 и/или il-13, и их применение | |
| JP2012100677A5 (enExample) | ||
| MA32621B1 (fr) | Traitement de maladie auto-immune et inflammatoire | |
| MXPA06012601A (es) | Anticuerpos especificos de fcy riib humanizados y metodos de uso de los mismos. | |
| JP2010516290A5 (enExample) | ||
| JP2014520148A (ja) | 治療のための神経筋接合部への標的化 | |
| JP2017502920A5 (enExample) | ||
| AU2023320453A1 (en) | Compositions and methods for crossing the blood brain barrier | |
| WO2006087637A3 (en) | Anti her2/neu antibody | |
| MA35233B1 (fr) | Molecules de liaison bispecifiques se liant à dii4 et ang2 | |
| JP2020072685A (ja) | クロストリジウム・ディフィシル感染症の治療のための、クロストリジウム・ディフィシルのトキシンａ及びトキシンｂに対する四重特異性の八量体型結合剤及び抗体 | |
| EP3292140A1 (en) | Cancer immunotherapeutic | |
| JPWO2020059847A5 (enExample) | ||
| JP7428404B2 (ja) | Ｇｓｘ１を使用した脊髄損傷（ｓｃｉ）および脳損傷の処置 | |
| CN111315779A (zh) | 抗-cd3抗体及包含其的用于癌症治疗的药物组合物 | |
| JP2009519025A5 (enExample) | ||
| Chan et al. | Mini-review on initiatives to interfere with the propagation and clearance of alpha-synuclein in Parkinson’s disease | |
| JP2022539758A (ja) | ハンチントン病を治療するための方法および材料 | |
| KR20210032412A (ko) | 말초신경장애, 또는 말초신경장애 혹은 성상세포장애가 인정되는 질환에 따른 동통의 예방 또는 치료 방법 |